Health TrialsbyHealthPanel

Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia

ConditionAML
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorSecond Hospital of Shanxi Medical University

About this trial

Patients diagnosed with acute myeloid leukemia in the Second Hospital of Shanxi Medical University were selected and divided into the newly diagnosed group, the relapsed group, the complete remission group as the experimental group, and the healthy physical examination subjects as the control group. The relationship between IL-1β, catecholamine and norkephalin in peripheral blood of the experimental group and the control group was observed. According to the literature, the experimental group was significantly higher than the control group. In the experimental group, the newly diagnosed group was higher than the relapse group, and the relapse group was higher than the complete remission group, and the correlation was positive, and the difference was statistically significant.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

In accordance with adult acute myeloid leukemia (non-acute promyelocytic leukemia)The diagnostic criteria for AML in the Chinese Diagnosis and Treatment Guidelines (2017 edition); ②Leukocyte count ≤ 25×109/L;

No treatment has been received in the past 6 months.

None of the candidates are related and known this study, and sign the informed consent.

Disqualifiers

Patients who are allergic to the drugs used in this study;

People with mental illness or cognitive impairment;

Patients with infectious diseases; ④Patients with severe heart, liver, kidney and other organ function lesions; ⑤ Combined with other malignant swelling. The tumor.

Trial population

Patients in the Second Hospital of Shanxi Medical University from June 2022 to November 2023

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

  • Enzyme-linked immunosorbent assay

    Diagnostic test

    Serum N/OFQ , IL-1β and NE levels were detected.

Treatment groups

80 Participants
are divided into 4 treatment groups
Group A: the newly diagnosed group1 intervention
Group B: the relapsed group1 intervention
Group C: the complete remission group1 intervention
Group D: the control group1 intervention

Trial outcomes

Primary outcomes

1

N/OFQ

Serum N/OFQ levels

Time frame
24 hours
2

IL-1β

Serum IL-1β levels

Time frame
24 hours
3

NE

Serum NE levels

Time frame
24 hours

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Second Hospital of Shanxi Medical University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: